NEULAND LABORATORIES LTD.

Neuland Laboratories Ltd announced board approval for a capital expenditure of ₹126 crores to acquire approximately 134 acres of land in Kakinada, Andhra Pradesh. This strategic acquisition is intended for future expansion of the company's operations. The company also holds a right of first refusal for an additional 66 acres, potentially increasing the total land parcel to 200 acres. The investment will be financed through internal accruals.

Malabar India Fund Limited has disclosed the sale of 2,72,634 equity shares, representing 2.12% of the total share capital, in Neuland Laboratories Ltd. The sale occurred in the open market between August 10, 2024, and August 14, 2026. Following the transaction, Malabar India Fund's shareholding in Neuland Laboratories has reduced from 7.18% to 5.06%. The total equity share capital of Neuland Laboratories remains unchanged at ₹12,82,98,890, comprising 1,28,29,889 equity shares of ₹10 each.

Neuland Laboratories Ltd has announced the completion of a US FDA inspection at its Unit 3 manufacturing facility in Gaddapotharam village, Sangareddy District, which took place from August 10th to 14th, 2026. The inspection resulted in one observation from the US FDA, pertaining to procedural improvements in water and environmental monitoring. The company plans to submit its response to the US FDA within the stipulated timelines. This update is crucial for investors monitoring regulatory compliance and operational standards.

Neuland Laboratories Ltd announced the execution of a corporate guarantee of ₹40 crores in favor of Gland Pharma Limited. This guarantee is in connection with a Loan Licence Agreement to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. The company also approved its unaudited financial results for the quarter ended June 30, 2026, and a capacity expansion at its Unit 1 facility. The guarantee represents a contingent liability with no immediate impact on the company's financials. The capacity expansion involves an investment of ₹39.8 crores and is expected to be completed in 6-7 months.

Neuland Laboratories Ltd announced board approval for a significant manufacturing capacity expansion at its Unit 1 in Telangana. The company will add 18 KL to its existing capacity, requiring an investment of ₹39.8 crores (including GST). This expansion is slated for completion within 6-7 months and will be financed through internal accruals, aimed at catering to growing customer demand. Additionally, the board approved the execution of a corporate guarantee of ₹40 crores in favor of Gland Pharma Limited for a loan license agreement to establish dedicated manufacturing capacity. The company also disclosed its unaudited financial results for the quarter ended June 30, 2026.

Neuland Laboratories Limited announced its financial results for the quarter ended June 30, 2026. Total income for Q1 FY27 stood at ₹650.1 crore, a significant increase of 116.3% year-on-year from ₹300.6 crore in Q1 FY26. EBITDA surged by 448.2% to ₹231.1 crore from ₹42.1 crore in the prior year's quarter. Profit After Tax (PAT) also saw a substantial jump of 975.0% to ₹147.4 crore from ₹13.7 crore in Q1 FY26. The company's CEO highlighted encouraging performance from CMS & GDS businesses and strong customer conversations, with plans for increased investment based on available opportunities. An earnings call is scheduled for August 5, 2026.

Neuland Laboratories Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors also approved a corporate guarantee of ₹40 crores in favor of Gland Pharma Limited for a Loan Licence Agreement. This agreement is to establish dedicated manufacturing capacity and incur capital expenditure for specific products. The company is also enhancing manufacturing capacity at Unit 1, with an investment of ₹39.8 crores funded through internal accruals, expected to be completed in 6-7 months. The corporate guarantee represents a contingent liability with no immediate impact on financials.

Neuland's consolidated Q1 FY27 revenue of ₹641.6 Cr (+119.2% YoY, -17.4% QoQ) and PAT of ₹147.7 Cr (+962% YoY, -30.6% QoQ) came in well above Street estimates of ₹419-482 Cr revenue and ₹18-23 Cr PAT (Univest's Q1 preview) — a clear beat on both lines, though the scale of the YoY jump is exaggerated by an unusually soft Q1 FY26 base (NPM then was just 4.6%, OPM 11.8%). Standalone tracked almost identically — PAT ₹147.4 Cr, EPS ₹114.86 versus ₹115.10 consolidated — so there's no material basis divergence this quarter. OPM came in at 34.7% and NPM at 22.7%, both sharply higher than a year ago (11.8%/4.6%) but down from Q4 FY26's 39.6%/27.0%. That sequential cooling is exactly what management flagged on the Q4 call, where it explicitly said the Q4 margins were not sustainable and future profitability would hinge on business mix and cost pressures. The expense build was broad-based rather than driven by one line: employee costs rose to ₹106.4 Cr from ₹73.5 Cr YoY and manufacturing expenses to ₹47.9 Cr from ₹39.4 Cr YoY as the topline scaled, while cost of materials grew more slowly (₹228.8 Cr vs ₹161.5 Cr YoY) — some operating leverage even as the margin percentage eased off the Q4 high. Management's only standing guidance is a long-term aspirational 18-20% revenue CAGR, with growth explicitly described as "lumpy, not linear" quarter to quarter — this quarter's sharp QoQ pullback in both revenue and profit is consistent with that framing rather than a red flag, so the print reads as on-guidance. The same day, the board approved a ₹40 Cr corporate guarantee backing a new long-term CDMO partnership with Gland Pharma to build a dedicated sterile API manufacturing suite (~1,400 kg of added annual capacity) at Gland's Vizag facility — CEO Saharsh Davuluri framed it as strengthening Neuland's "differentiated platform" in complex, sterile APIs, tying into the company's stated capital-deployment focus on peptide manufacturing and R&D expansion. The board separately cleared an ₹39.8 Cr, 18 KL capacity addition at Unit 1 (Bonthapally), funded via internal accruals, alongside confirmation that the previously flagged expanded units began production on July 31, 2026.

Neuland Laboratories Ltd has announced the commencement of commercial production for additional capacities at its Unit 1 and Unit 3 facilities. This expansion is part of the company's ongoing growth plans. The units are located in Bonthapally Village and Gaddapotharam Village, respectively, in the Sangareddy District of Telangana, India. This development signifies progress in the company's manufacturing capabilities and is expected to support future growth and operational efficiency.

Neuland Laboratories Ltd has announced that its Board of Directors will convene on August 5, 2026. The primary agenda item for this meeting is to consider and approve the unaudited financial results, both standalone and consolidated, for the first quarter ended June 30, 2026. Additionally, the company confirmed that the trading window for its equity shares will remain closed from July 1, 2026, until 48 hours after the declaration of these financial results, in accordance with the company's Insider Trading Code.